ArticleResearch in pharmaceutical sciences2018
The protective role of melatonin in cadmium-induced proliferation of ovarian cancer cells.
Article in Research in pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Methamphetamine exposure during gestation and lactation periods impairs the learning and memory of offspring mice, which is reversed by melatonin: the role of oxidative stress and acetylcholinesterase.Research in pharmaceutical sciences · 2025Article
- Adjuvant melatonin therapy during exercise prescription in breast cancer survivors on physical and anthropometric parameters, quality of life, and hormonal response. A randomized controlled trial.Frontiers in sports and active living · 2025Article
- The effects of chitosan-loaded JQ1 nanoparticles on OVCAR-3 cell cycle and apoptosis-related gene expression.Research in pharmaceutical sciences · 2024Article
- An overview of the ameliorative efficacy ofFrontiers in public health · 2024Review
- Antioxidant and genoprotective effects of osthole against cadmium-induced DNA damage: anResearch in pharmaceutical sciences · 2022Article
- Curative Potential of Substances with Bioactive Properties to Alleviate Cd Toxicity: A Review.International journal of environmental research and public health · 2022Review
- Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.Molecules (Basel, Switzerland) · 2021Review
- Effects of melatonin on uterine hypertrophy/hyperplasia: A preliminary experimental rat study.Heliyon · 2020Article
- The Role of Natural Antioxidants Against Reactive Oxygen Species Produced by Cadmium Toxicity: A Review.Advanced pharmaceutical bulletin · 2020Review
- Melatonin and its ubiquitous anticancer effects.Molecular and cellular biochemistry · 2019Review
- Melatonin May Increase Anticancer Potential of Pleiotropic Drugs.International journal of molecular sciences · 2018Review
- Cadmium induces progesterone receptor gene expression via activation of estrogen receptor in human ovarian cancer cells.Research in pharmaceutical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadmium (Cd), a ubiquitous environmental and occupational pollutant, acts as a metalloestrogen to induce cell proliferation. It is suggested that Cd may also contribute to the development of estrogen-related cancers like ovarian cancer which is the most lethal cancer in women. Furthermore, it was shown that melatonin has antiproliferative effect on estradiol (E2)-induced proliferation. The aim of the present study was to evaluate whether melatonin inhibits Cd-induced proliferation in ovarian cancer cell lines and also whether Cd and melatonin can modulate estrogen receptor α (ERα) expression. OVCAR3 and SKOV3 human ovarian cancer cell lines were treated with CdCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.